Could multiple myeloma patients get their infusions at home?
NCT ID NCT05511428
First seen Nov 21, 2025 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This study tested whether giving Darzalex Faspro (a drug for multiple myeloma) at home is practical and satisfactory for patients. Twenty adults with multiple myeloma who were already on a monthly daratumumab regimen received their injections at home. The main goal was to measure treatment satisfaction using a questionnaire. The study also tracked how well patients stuck to their home treatment schedule.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Daratumumab and hyaluronidase (Darzalex Faspro)
What this could lead to
If successful, this could show that giving multiple myeloma treatment at home is safe and satisfactory, reducing the need for frequent hospital visits.
What could go wrong
This was a very small study (20 people) with no comparison group, so results may not apply to everyone. It focused on satisfaction, not on whether the drug works better or worse at home.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.